Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 50 articles: HTML format

Single Articles

July 2024
1. FARAJ KS, Oerline M, Kaufman SR, Dall C, et al
   Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.
   J Natl Cancer Inst. 2024 Jul 25:djae155. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2024
2. DING CC, Tony Su Z, Erak E, DePaula Oliveira L, et al
   Predicting prostate cancer grade reclassification on active surveillance using a deep Learning-Based grading algorithm.
   J Natl Cancer Inst. 2024 Jun 18:djae139. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2024
3. BJORNEBO L, Razdan S, Discacciati A, Palsdottir T, et al
   Prostate Cancer Incidence and Mortality in Men Exposed to alpha1-Adrenoceptor Antagonists.
   J Natl Cancer Inst. 2024 May 8:djae108. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2024
4. BASU A, Rais-Bahrami S
   Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
   J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093.
   PubMed    
   
   
   
5. LAO Y, Guan X, Wang J, Bai Y, et al
   RE: Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study.
   J Natl Cancer Inst. 2024 Feb 12:djae032. doi: 10.1093.
   PubMed    
   
   
   January 2024
6. LEE KM, Nelson T, Bryant A, Teerlink C, et al
   Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
   J Natl Cancer Inst. 2024 Jan 11:djae002. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. WILKINSON S, Sowalsky AG
   Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.
   J Natl Cancer Inst. 2024;116:12-14.
   PubMed    
   
   
   
8. FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al
   Changes in cancer-related mortality during the COVID-19 pandemic in the United States.
   J Natl Cancer Inst. 2024;116:167-169.
   PubMed     Abstract available
   
   
   December 2023
9. CRUMP C, Stattin P, Brooks JD, Sundquist J, et al
   Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study.
   J Natl Cancer Inst. 2023 Dec 7:djad257. doi: 10.1093.
   PubMed     Abstract available
   
   
   November 2023
10. FREEMAN JR, Saint-Maurice PF, Watts EL, Moore SC, et al
    Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.
    J Natl Cancer Inst. 2023 Nov 28:djad210. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. COOPERBERG MR
    Can early prostate cancer screening help address mortality disparities among Black men?
    J Natl Cancer Inst. 2023 Nov 10:djad217. doi: 10.1093.
    PubMed    
    
    
    October 2023
12. HU S, Chang CP, Snyder J, Deshmukh V, et al
    Mental health outcomes in a population-based cohort of patients with prostate cancer.
    J Natl Cancer Inst. 2023 Oct 23:djad175. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. MA T, Jin L, Bai S, Liu Z, et al
    Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate Cancer Progression.
    J Natl Cancer Inst. 2023 Oct 17:djad215. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
14. KENSLER KH, Johnson R, Morley F, Albrair M, et al
    Prostate Cancer Screening in African American Men: A Review of the Evidence.
    J Natl Cancer Inst. 2023 Sep 15:djad193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. SUMIYOSHI T, Wang X, Warner EW, Sboner A, et al
    Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.
    J Natl Cancer Inst. 2023 Sep 7:djad184. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2023
16. DANIELS JP, Freedland SJ, Gresham G
    The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
    J Natl Cancer Inst. 2023 Aug 16:djad140. doi: 10.1093.
    PubMed    
    
    
    
17. WOLINSKY H
    Re: Putting patients first to redefine prostate cancer classifications: Patients' viewpoints on redefining Grade Group 1.
    J Natl Cancer Inst. 2023 Aug 16:djad160. doi: 10.1093.
    PubMed    
    
    
    July 2023
18. YOO M, Nelson RE, Haaland B, Dougherty M, et al
    Cost-Effectiveness Analysis of seven treatments In Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Public-Payer Perspective.
    J Natl Cancer Inst. 2023 Jul 12:djad135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. NYAME YA, Gore JL, Lin DW
    Putting patients first to redefine prostate cancer classifications.
    J Natl Cancer Inst. 2023 Jul 10:djad124. doi: 10.1093.
    PubMed    
    
    
    June 2023
20. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. LUYENDIJK M, Visser O, Blommestein HM, de Hingh IHJT, et al
    Changes in survival in de novo metastatic cancer in an era of new medicines.
    J Natl Cancer Inst. 2023;115:628-635.
    PubMed     Abstract available
    
    
    
22. BERLIN A, Ramotar M, Santiago AT, Liu Z, et al
    The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.
    J Natl Cancer Inst. 2023 Jun 7:djad108. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2023
23. CHU CE, Leapman MS, Zhao S, Cowan JE, et al
    Prostate cancer disparities among American Indians/Alaskan Natives in the United States.
    J Natl Cancer Inst. 2023 Jan 11:djad002. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. HAIMAN CA, Kote-Jarai Z, Darst BF, Conti DV, et al
    RE: Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
    J Natl Cancer Inst. 2023 Jan 11:djad005. doi: 10.1093.
    PubMed    
    
    
    
25. HOULAHAN KE, Livingstone J, Fox NS, Kurganovs N, et al
    A polygenic two-hit hypothesis for prostate cancer.
    J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2022
26. HU X, Lipscomb J, Jiang C, Graetz I, et al
    Vertical integration of oncologists and cancer outcomes and costs in metastatic Castration-Resistant prostate cancer.
    J Natl Cancer Inst. 2022 Dec 30:djac233. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2022
27. 
    Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade.
    J Natl Cancer Inst. 2022 Nov 15. pii: 6827851. doi: 10.1093.
    PubMed    
    
    
    October 2022
28. PAGADALA MS, Lynch J, Karunamuni R, Alba PR, et al
    Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
    J Natl Cancer Inst. 2022 Oct 28. pii: 6777270. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. SHIH YT, Xu Y, Bradley C, Giordano SH, et al
    Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
    J Natl Cancer Inst. 2022;114:1392-1399.
    PubMed     Abstract available
    
    
    September 2022
30. AWASTHI S, Grass GD, Torres-Roca J, Johnstone PAS, et al
    Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease.
    J Natl Cancer Inst. 2022 Sep 2. pii: 6687132. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2022
31. TAKAHASHI T
    RE: Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Jul 26. pii: 6650145. doi: 10.1093.
    PubMed    
    
    
    June 2022
32. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed     Abstract available
    
    
    April 2022
33. LAI LY, Oerline MK, Caram MEV, Tsao PA, et al
    Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. KEATING NL
    Cardiovascular and Metabolic Diagnoses Associated with Novel Hormonal Agents for Prostate Cancer in Non-Trial Populations.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568021. doi: 10.1093.
    PubMed    
    
    
    
35. QIAO EM, Lynch JA, Lee KM, Kotha NV, et al
    Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
    J Natl Cancer Inst. 2022;114:592-599.
    PubMed     Abstract available
    
    
    March 2022
36. BORREGALES LD, DeMeo G, Gu X, Cheng E, et al
    Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Mar 28. pii: 6555003. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
37. MARK M, von Moos R, Cathomas R, Stoffel S, et al
    RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Nov 29. pii: 6446038. doi: 10.1093.
    PubMed    
    
    
    October 2021
38. MITCHELL AP, Mishra A, Panageas KS, Lipitz-Snyderman A, et al
    Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Oct 1. pii: 6379715. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
39. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
    Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. HAWLEY JE, Pan S, Kandadi H, Chaimowitz MG, et al
    Analysis of Circulating Immune Biomarkers by Race in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Sipuleucel-T.
    J Natl Cancer Inst. 2021 Jul 24. pii: 6327691. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
42. BRAWLEY OW, Paller CJ
    The Realities of Prostate Cancer Screening, Treatment, and Race.
    J Natl Cancer Inst. 2021 May 8. pii: 6272521. doi: 10.1093.
    PubMed    
    
    
    
43. NYAME YA, Gulati R, Heijnsdijk EAM, Tsodikov A, et al
    The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    J Natl Cancer Inst. 2021 May 8. pii: 6272520. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. OLSSON H, Nordstrom T, Jaderling F, Egevad L, et al
    Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
    J Natl Cancer Inst. 2021;113:632-640.
    PubMed     Abstract available
    
    
    
45. BECKER DJ, Rude T, Walter D, Wang C, et al
    The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
    J Natl Cancer Inst. 2021;113:626-631.
    PubMed     Abstract available
    
    
    April 2021
46. KLEBANER D, Travis Courtney P, Garraway IP, Einck J, et al
    Association of Health-Care System with Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.
    J Natl Cancer Inst. 2021 Apr 21. pii: 6248098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. WANG L, Paller C, Hong H, Rosman L, et al
    Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    J Natl Cancer Inst. 2021 Apr 8. pii: 6217361. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2020
48. HEWITT SM
    The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making.
    J Natl Cancer Inst. 2020;112:1079-1080.
    PubMed    
    
    
    October 2020
49. FEDEWA SA, Ma J, Jemal A
    Response to Lehrer and Rheinstein.
    J Natl Cancer Inst. 2020;112:1069-1070.
    PubMed    
    
    
    September 2020
50. BROWN DW, Machiela MJ
    Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk.
    J Natl Cancer Inst. 2020;112:871-872.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.